Literature DB >> 8549808

RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen gamma-chain C-terminal peptide.

K H Mayo1, F Fan, M P Beavers, A Eckardt, P Keane, W J Hoekstra, P Andrade-Gordon.   

Abstract

Fibrinogen gamma-chain C-terminal peptide HHLG-GAKQAGDV (gamma 12) and alpha-chain peptide GRGDSP are known to inhibit fibrinogen-mediated platelet cell aggregation via competitive interactions with platelet integrin receptor GPIIb/IIIa. NMR studies of gamma 12 in the presence of purified GPIIb/IIIa in SDS/water solution have demonstrated the presence of two gamma 12 binding states, one of which is eliminated by GRGDSP (RGD) up to a RGD: gamma 12 ratio of 2:1. RGD: gamma 12 ratios greater than 2:1 produce multiple sets of gamma 12 NMR signals in TOCSY spectra. At a ratio of 4:1, two to four such resonance sets can be resolved for A405, Q407, A408, G409, D410 and V411 spin systems. The number of multiple resonances remains unchanged at ratios of 6:1 and 8:1. Addition of gamma 12 to reverse the ratio to 8:8 (1:1) has no apparent effect on the RGD-induced distribution. Results suggest that RGD irreversibly induces a conformational transition(s) in GPIIb/IIIa to produce multiple gamma 12 binding sites on the receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8549808     DOI: 10.1016/0014-5793(95)01418-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  The two phenylalanines in the GFFKR motif of the integrin alpha6A subunit are essential for heterodimerization.

Authors:  A A De Melker; D Kramer; I Kuikman; A Sonnenberg
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

2.  Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization.

Authors:  Jie Su; Hongying Gan-Schreier; Benjamin Goeppert; Walee Chamulitrat; Wolfgang Stremmel; Anita Pathil
Journal:  Int J Mol Sci       Date:  2018-10-20       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.